Phibro Animal Health (NASDAQ:PAHC) CEO Sells $392,832.00 in Stock

Posted by Renee Jackson on May 7th, 2026

Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the transaction, the chief executive officer directly owned 67,720 shares in the company, valued at approximately $3,778,776. This represents a 9.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

On Thursday, May 7th, Jack Bendheim sold 4,528 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.49, for a total value of $219,562.72.
On Thursday, April 30th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.76, for a total value of $371,430.40.
On Tuesday, April 28th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $55.91, for a total transaction of $393,606.40.
On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.29, for a total transaction of $382,201.60.
On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $54.64, for a total value of $384,665.60.
On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $59.08, for a total value of $415,923.20.
On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.68, for a total value of $556,300.80.
On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.66, for a total transaction of $272,764.80.
On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total value of $258,244.80.

Phibro Animal Health Stock Performance

Shares of PAHC traded down $15.34 during mid-day trading on Thursday, hitting $43.16. 1,572,579 shares of the company’s stock were exchanged, compared to its average volume of 288,152. Phibro Animal Health Corporation has a fifty-two week low of $19.17 and a fifty-two week high of $60.08. The firm has a market capitalization of $1.75 billion, a P/E ratio of 19.18, a P/E/G ratio of 0.86 and a beta of 0.61. The business’s 50 day moving average is $53.90 and its two-hundred day moving average is $46.51. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities analysts expect that Phibro Animal Health Corporation will post 3.03 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be given a $0.12 dividend. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.1%. Phibro Animal Health’s dividend payout ratio is currently 21.33%.

Analyst Ratings Changes

A number of brokerages have weighed in on PAHC. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, Citigroup initiated coverage on shares of Phibro Animal Health in a research report on Wednesday, April 15th. They set a “neutral” rating and a $62.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $42.40.

Get Our Latest Analysis on Phibro Animal Health

Key Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

Positive Sentiment: Quarterly results beat expectations — Phibro reported $0.76 EPS vs. $0.72 consensus and revenue of $383.5M vs. $367.0M expected; net sales rose ~10% year-over-year and net income increased ~15%, highlighting continued top-line growth and margin improvement. Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Positive Sentiment: Earnings/analyst coverage echoed the beat — multiple outlets and the company transcript highlight the upside vs. estimates, providing evidence the quarter was fundamentally stronger than consensus. Earnings Transcript and Summary
Neutral Sentiment: FY2026 guidance updated to $2.98–$3.10 EPS and revenue ~ $1.5B (range provided by company). The midpoint is close to analyst expectations (~$3.03), but the range left some uncertainty about the low end. Investors often react to the tone and range width as much as the midpoint. Updated Financial Guidance
Neutral Sentiment: Dividend declared — company announced a $0.12 quarterly dividend (record June 3, payable June 24), a small yield that supports income-focused holders but is unlikely to materially change valuation. (Company release)
Neutral Sentiment: Investor events and outreach — management will present at the Bank of America Healthcare Conference next week, offering an opportunity for real-time analyst Q&A and potential clarity on strategy and guidance execution. Conference Participation Announcement
Neutral Sentiment: Corporate sustainability initiative launched — new VERRATAIN™ sustainability platform and VAXA partnership may improve ESG positioning over time but is unlikely to drive near-term revenue. Sustainability Platform Announcement
Negative Sentiment: Revolving credit facility expansion raised investor concerns — coverage notes the company expanded its credit line, which some investors read as higher leverage risk or preparation for contingencies; combined with the company’s stated debt/equity profile, this likely increased selling pressure today. Investors Reacting to Revolving Credit Facility Expansion

Institutional Trading of Phibro Animal Health

Several large investors have recently added to or reduced their stakes in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after buying an additional 546 shares during the period. Millennium Management LLC increased its position in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after purchasing an additional 154,281 shares in the last quarter. Jane Street Group LLC increased its position in shares of Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after purchasing an additional 13,404 shares in the last quarter. Cetera Investment Advisers grew its holdings in Phibro Animal Health by 63.0% during the 2nd quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock worth $481,000 after acquiring an additional 7,280 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after acquiring an additional 363 shares during the last quarter. 99.34% of the stock is owned by institutional investors.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.